Can an old alcohol-dependence drug help the immune system fight brain cancer?

NCT ID NCT07719127

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 1 trial tests whether disulfiram, a drug long used for alcohol dependence, can reduce immune suppression caused by high-grade gliomas. Participants take disulfiram for 3 to 14 days before their scheduled tumor-removal surgery. The goal is to see if the drug can dampen the tumor's ability to block immune cells and lessen brain swelling, potentially reducing the need for steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
disulfiram, a drug used for alcohol dependence, repurposed to target immune suppression in brain tumors
What this could lead to
If successful, this could point toward a way to make brain tumors more responsive to the immune system and reduce reliance on steroids.
What could go wrong
This is a very early phase 1 trial with only 20 participants, so results may not apply broadly. Disulfiram may not effectively alter the tumor environment or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN (NERVOUS SYSTEM) CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.